MEI Pharma Reports Topline Data From Phase I Trial Of ME-344 - Quick Facts

(RTTNews) - MEI Pharma Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced that data from the ongoing Phase I clinical trial of its mitochondrial inhibitor drug candidate ME-344 in patients with refractory solid tumors will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

The company said, eight of the 23 patients evaluable for efficacy (35%) achieved disease control, including one confirmed partial response in a patient with refractory small cell lung cancer and seven patients with prolonged stable disease ranging from 8 to 40+ weeks. The maximum tolerated dose was established at 10 mg/kg delivered on a weekly schedule. Dose limiting toxicity of Grade 3 neuropathy was observed at 15 mg/kg and 20 mg/kg.

ME-344 is MEI Pharma's next-generation mitochondrial inhibitor drug candidate and an active metabolite of NV-128, the company's first-generation compound. MEI Pharma owns exclusive worldwide rights to ME-344.